Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States

References

• Mannucci PM, Tuddenham EG. The hemophilias — from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi:10.1056/NEJM200106073442307
   PubMed Web of Science ®Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al.; Data Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. doi:10.7326/M19-1208
   PubMed Web of Science ®Google Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038–2044. doi:10.1182/blood-2015-01-528414
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al.; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47. doi:10.1111/j.1365-2516.2012.02909.x
   PubMed Web of Science ®Google Scholar
• Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7(4):392–396. doi:10.1046/j.1365-2516.2001.00534.x
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin Investig Drugs. 2020;29(3):303–309. doi:10.1080/13543784.2020.1723547
   PubMed Web of Science ®Google Scholar
• Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol. 2015;169(6):768–776. doi:10.1111/bjh.13360
   PubMed Web of Science ®Google Scholar
• Biogen Inc. ELOCTATE® [antihemophilic factor (recombinant), Fc fusion protein] lyophilized powder for solution for intravenous injection; 2014. Available from: https://www.fda.gov/media/88746/download. Accessed January 27, 2020.
   Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al.; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317–325. doi:10.1182/blood-2013-10-529974
   PubMed Web of Science ®Google Scholar
• Baxalta US Inc. ADYNOVATE, antihemophilic factor (recombinant), PEGylated lyophilized powder for solution for intravenous injection; 2021. Available from: https://www.fda.gov/media/94470/download. Accessed January 27, 2020.
   Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078–1085. doi:10.1182/blood-2015-03-630897
   PubMed Web of Science ®Google Scholar
• Chowdary P, Mullins ES, Konkle BA, et al. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia. 2020;26(4):e168–e178. doi:10.1111/hae.14052
   PubMed Web of Science ®Google Scholar
• Aledort L, Milligan S, Watt M, Booth J. A retrospective observational study of rurioctocog alfa pegol in clinical practice in the United States.. J Manag Care Spec Pharm. 2020;26(4):492–503. doi:10.18553/jmcp.2020.26.4.492
   PubMed Web of Science ®Google Scholar
• Keepanasseril A, Stoffman J, Bouskill V, et al. Switching to extended half-life products in Canada - preliminary data. Haemophilia. 2017;23(4):e365–e367. doi:10.1111/hae.13245
   PubMed Web of Science ®Google Scholar
• Teitel J, Sholzberg M, Iorio A. Extended half-life factor VIII concentrates in adults with hemophilia A: comparative pharmacokinetics of two products. Res Pract Thromb Haemost. 2021;5(2):349–355. doi:10.1002/rth2.12476
   PubMed Web of Science ®Google Scholar
• Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference? J Thromb Haemost. 2019;17(7):1085–1096. doi:10.1111/jth.14469
   PubMed Web of Science ®Google Scholar
• Su J, Li N, Joshi N, et al. Patient and caregiver preferences for haemophilia A treatments: a discrete choice experiment. Haemophilia. 2020;26(6):e291–e299. doi:10.1111/hae.14137
   PubMed Web of Science ®Google Scholar
• Valentino LA, Pipe SW, Collins PW, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016;22(4):514–520. doi:10.1111/hae.12905
   PubMed Web of Science ®Google Scholar
• Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021;137(13):1818–1827. doi:10.1182/blood.2020005673
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–553. doi:10.3324/haematol.2019.232132
   PubMed Web of Science ®Google Scholar
• Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186–192. doi:10.1097/MBC.0000000000000885
   PubMed Web of Science ®Google Scholar
• Booth J, Lu M, Bron M, Hafeman A. Real world dosing and therapy switching patterns of rFVIII-Fc from specialty pharmacy providers in the United States. Poster presented at: WFH World Congress; July 24–28; 2016; Orlando, FL, USA. Available from: https://www.postersessiononline.eu/173580348_eu/congresos/WFH2016/aula/-PP-T_66_WFH2016.pdf. Accessed August 31, 2022.
   Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269–275. doi:10.1111/j.1538-7836.2009.03703.x
   PubMed Web of Science ®Google Scholar